Glaukos Corporation

Valuation Analysis

About the Company

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used

Glaukos Corporation Stock at a Glance

Glaukos Corporation (GKOS) is currently trading at $126.81 with a market capitalization of $7.4B. The 52-week range spans from $73.16 to $148.11; the current price is 14.4% below the yearly high. Year-over-year revenue growth stands at +41.2%.

💰 Dividend

Glaukos Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

12 analysts rate Glaukos Corporation (GKOS) on consensus: Strong Buy. The average price target is $156.33, implying +23.28% from the current price. Analyst price targets range from $136.00 to $170.00.

Glaukos Corporation: The Investment Case in Detail

Glaukos Corporation (GKOS) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Top-line momentum is unusually strong with revenue expanding 41.2% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 78.08%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 23.28% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

What to Watch Next

• The analyst consensus price target implies 23.28% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (6.44%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Glaukos Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.